17-15239584-A-T
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000494511.7(PMP22):c.2T>A(p.Met1?) variant causes a start lost change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
ENST00000494511.7 start_lost
Scores
Clinical Significance
Conservation
Publications
- Charcot-Marie-Tooth disease type 1AInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), ClinGen, Laboratory for Molecular Medicine, Ambry Genetics
- hereditary neuropathy with liability to pressure palsiesInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet
- Charcot-Marie-Tooth disease type 1EInheritance: AD Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Ambry Genetics, PanelApp Australia, Orphanet, Labcorp Genetics (formerly Invitae)
- Charcot-Marie-Tooth disease type 3Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt | 
|---|---|---|---|---|---|---|---|---|
| PMP22 | NM_000304.4 | c.206T>A | p.Met69Lys | missense_variant | Exon 4 of 5 | ENST00000312280.9 | NP_000295.1 | 
Ensembl
Frequencies
GnomAD3 genomes  
GnomAD4 exome Cov.: 33 
GnomAD4 genome  
ClinVar
Submissions by phenotype
Charcot-Marie-Tooth disease, type IA    Pathogenic:1 
The missense variant c.206T>A (p.Met69Lys) in PMP22 gene has been reported previously in heterozygous state in individuals affected with Charcot-MarieTooth disease, type 1A (Chundi Vinay Kumar et al., 2014). Functional studies have demonstrated that the M69K variant impairs and destabilizes the PMP22 protein (Schleback et al., 2015). The p.Met69Lys variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. It has been submitted to ClinVar as Pathogenic. The amino acid Met at position 69 is changed to a Lys changing protein sequence and it might alter its composition and physicochemical properties. The amino acid change p.Met69Lys in PMP22 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. -
DEJERINE-SOTTAS SYNDROME, AUTOSOMAL DOMINANT    Pathogenic:1 
- -
not provided    Pathogenic:1 
The M69K missense variant in the PMP22 gene has been reported previously as a de novo change in an individual with Dejerine-Sottas syndrome (Roa et al., 1993). Functional studies have demonstrated that the M69K variant impairs and destabilizes the PMP22 protein (Schleback et al., 2015). The M69K variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The M69K variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Additionally, missense variants at the same (M69R) in nearby residues (A67T/P/D, L71P, S72P/W/L) have been reported in Human Gene Mutation Database in association with PMP22-related neuropathies (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, this variant is interpreted to be a pathogenic variant and its presence is consistent with the diagnosis in this patient. -
Charcot-Marie-Tooth disease, type I    Pathogenic:1 
This sequence change replaces methionine, which is neutral and non-polar, with lysine, which is basic and polar, at codon 69 of the PMP22 protein (p.Met69Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Dejerine-Sottas syndrome (PMID: 8275092). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 8432). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PMP22 protein function. Experimental studies have shown that this missense change affects PMP22 function (PMID: 26102530). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at